◀ Back to CD4

CD4 — CD40LG

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: CD4 → CD40LG (decreases) Cotter et al., J Virol 2001*
  Evidence: The addition of CD40L (2 microg/ml) to cultures of human monocyte derived macrophages (MDM) led to a 40% reduction in CD4 cell surface expression. This downregulation in CD4 was specific, as antibodies to CD40L were able to reverse the effect.

Text-mined interactions from Literome

Tan et al., J Immunol 1999 (Lymphocytic Choriomeningitis...) : Altogether, these results indicate that T cells have distinct costimulatory requirements : optimal CD8 responses require 4-1BBL dependent interactions, whereas CD4 responses are minimally affected by 4-1BB costimulation, but require CD40-CD40L and B7-dependent interactions
Andersen et al., Int Immunol 1999 (Rhabdoviridae Infections) : CD4 ( + ) T cell mediated protection against a lethal outcome of systemic infection with vesicular stomatitis virus requires CD40 ligand expression, but not IFN-gamma or IL-4
Blair et al., J Exp Med 2000 : CD40 ligand ( CD154 ) triggers a short-term CD4 ( + ) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis
Lode et al., J Clin Invest 2000 (Melanoma, Experimental) : Melanoma immunotherapy by targeted IL-2 depends on CD4 ( + ) T-cell help mediated by CD40/CD40L interaction ... Three lines of evidence show that CD4 ( + ) T-cell help was mediated by CD40/CD40L interaction but not by endogenous IL-2 production
Ensminger et al., Transplantation 2000 (Arteriosclerosis) : In this study, we have used a model of transplant arteriosclerosis to investigate whether CD4+ and CD8+ T cells are differentially affected by CD154 blockade
Bergamini et al., J Infect Dis 2002 (HIV Infections) : CD40L increased the number of CD4 and CCR5 antibody binding sites and the percentage of CD4- and CCR5 expressing cells
Amrani et al., Immunity 2002 (Diabetes Mellitus, Type 1) : In contrast, the autoreactive CD4 ( + ) T cells maturing in 4.1-NOD.RAG-2 ( -/- ) mice lost their diabetogenic potential if they lacked CD154 , even in the presence of CD154 ( + ) CD4 ( + ) T cells, B7.1 molecules on beta cells, CpG-DNA treatment, or systemic CD40 ligation
Wheat et al., Med Mycol 2002 (Histoplasmosis) : CD40L reduced fungal burden by less than one log when started two days before infection but did not act synergistically with low-dosage amphotericin B ( 0.2 mg kg ( -1 ) qod ) in CD4 depleted mice
Buisson et al., Vaccine 2003 : Cognate CD4 ( + ) T-cell help mediated by CD40L along with DC stimulation with another T-cell effector molecule, termed lymphocyte activated gene-3 ( LAG-3 or CD223, a ligand for MHC class II ) have been shown to induce this maturation process
Chougnet et al., J Leukoc Biol 2003 (Disease Models, Animal...) : However, a transcriptional defect in CD40L expression, mediated by the engagement of CD4 by HIV gp120, appears to play a primary role
Subauste et al., J Infect Dis 2004 (AIDS-Related Opportunistic Infections...) : Expression of CD154 in response to these pathogens was impaired in CD4 ( + ) T cells from HIV infected patients
Oderup et al., Transplantation 2006 : Previous studies have demonstrated that anti-CD40L or anti-B7 requires the presence of CD4 ( + ) CD25 ( + ) regulatory T cells ( Treg ) to induce antigen specific hyporesponsiveness
Xydia et al., Immunol Cell Biol 2011 : Combined activation of CD4 ( + ) and CD8 ( + ) memory T cells ( Tmem ) induced an increased expression of CD40L and CD40 on both populations ... Subsequently, CD40/CD40L caused a bi-directional stimulation of CD40 ( + ) CD4 ( + ) T(EM) by CD40L ( + ) CD8 ( + ) T(EM) and of CD40 ( + ) CD8 ( + ) T(EM) by CD40L ( + ) CD4 ( + ) T(EM)
Dodd-o et al., Am J Transplant 2011 : CD154 blockade abrogates allospecific responses and enhances CD4 ( + ) regulatory T-cells in mouse orthotopic lung transplant
Fanslow et al., J Immunol 1994 : In addition to its action on B lymphocytes, this report demonstrates that CD40L induced both CD4+ and CD8+ T cells isolated from murine lymphoid tissues to proliferate in the presence of submitogenic dosages of Con A, PHA, CD3 mAb, and TCR-alpha beta mAb